Misplaced Pages

Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD). It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β₂-adrenergic agonist).

Common side effects include sore throat, muscle cramps, and nausea. Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections. Safety in pregnancy is unclear.

The combination was approved for medical use in the United States in 1996. It is available as a generic medication. In 2022, it was the 178th most commonly prescribed medication in the United States, with more than 2 million prescriptions.

Medical uses

Ipratropium bromide/salbutamol can be used for the treatment of COPD and asthma.

Society and culture

Since Combivent contains a chlorofluorocarbon-based propellant, its use was discontinued in 2013 in the United States and other countries. This is because chlorofluorocarbons are attributed to depletion of the ozone layer.

References

1. ^ "Combivent Respimat- ipratropium bromide and albuterol spray, metered". DailyMed. 24 January 2022. Retrieved 30 October 2022.
2. "DuoNeb". DailyMed. Retrieved 30 October 2022.
3. "Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol". DailyMed. Retrieved 30 October 2022.
4. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
5. ^ Gordon J, Panos RJ (March 2010). "Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease". Expert Opinion on Drug Metabolism & Toxicology. 6 (3): 381–92. doi:10.1517/17425251003649549. PMID 20163324. S2CID 31806856.
6. "Albuterol / ipratropium Use During Pregnancy". Drugs.com. Retrieved 19 April 2019.
7. "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 18 April 2019.
8. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
9. "Albuterol; Ipratropium Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
10. Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, et al. (April 2016). "Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial". BMC Pulmonary Medicine. 16 (1): 65. doi:10.1186/s12890-016-0223-3. PMC 4851785. PMID 27130202.
11. "Phase Out of Combivent Inhalation Aerosol - Questions and Answers". FDA. 3 November 2018.

• Medicine

• Beta-adrenergic agonists
• Combination COPD drugs
• Drugs developed by Boehringer Ingelheim
• Bronchodilators
• Muscarinic antagonists